SCHEMBL2835940

SCHEMBL2835940

CCOC(=O)c1cc(NC(=O)c2ccccc2)n(-c2ccccc2)n1

nearest known ligand 0.65

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.65
KMT2A Q03164 5/20 0.64
ALDH1A1 P00352 2/20 0.58
MAPT P10636 2/20 0.57
GRM5 P41594 3/20 0.57
MEN1 O00255 2/20 0.57
TP53 P04637 2/20 0.56
THRB P10828 1/20 0.56
LMNA P02545 1/20 0.56
POLB P06746 1/20 0.54
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5397245 0.89 KMT2A (0.57) GAAKMT2AALDH1A1MAPTMEN1
SCHEMBL12100342 0.85 KMT2A (0.57) GAAKMT2AALDH1A1MAPTMEN1
SCHEMBL12100435 0.85 KMT2A (0.52) GAAKMT2AALDH1A1MAPTMEN1
SCHEMBL2838354 0.83 KMT2A (0.60) GAAKMT2AALDH1A1MAPTMEN1
SCHEMBL30719026 0.83 KMT2A (0.50) GAAKMT2AALDH1A1MAPTMEN1
SCHEMBL12100825 0.83 KMT2A (0.55) GAAKMT2AALDH1A1MAPTMEN1
SCHEMBL18694403 0.83 KMT2A (0.55) GAAKMT2AALDH1A1MAPTMEN1
SCHEMBL12100316 0.82 GAA (0.70) GAAKMT2AGRM5MEN1LMNA
SCHEMBL17186891 0.81 NTRK1 (0.54)
SCHEMBL17187108 0.81 NTRK1 (0.52) ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3162798-A1 5-MEMBERED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2017-05-03 EP disclosed
EP-2196459-B1 5-MEMBERED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL (JP) 2016-11-02 EP disclosed
US-8962671-B2 Amino-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals SANOFI (FR) 2015-02-24 US disclosed
EP-2668167-B1 AMINO-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2014-12-17 EP disclosed
EP-2668167-A1 AMINO-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2013-12-04 EP disclosed
US-8334301-B2 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-18 US disclosed
US-20120232112-A1 AMINO-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2012-09-13 US disclosed
WO-2012101199-A1 AMINO-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2012-08-02 WO disclosed
US-20100210696-A1 5-MEMBERED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-19 US disclosed
EP-2196459-A1 5-MEMBERED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-06-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210696-A1 5-MEMBERED HETEROCYCLIC COMPOUND NPY4R, NPY5R, NPY1R GAA 1513/4885KMT2A 4103/4885ALDH1A1 2505/4885
US-20120232112-A1 AMINO-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS CTSF, CTSS, CTSE GAA 66/4885KMT2A 4182/4885ALDH1A1 862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.